Sacituzumab Tirumotecan (sac-TMT) in Combination with Pembrolizumab for First-Line Treatment of PD-L1-Positive NSCLC Published in The Lancet

‘Critically important’: Upfront sacituzumab govitecan combo benefits breast cancer subset

CHICAGO — New findings from the randomized phase 3 ASCENT-04 trial reinforce prior research that first-line sacituzumab govitecan plus pembrolizumab should be “standard of care” for PD-L1-positive metastatic…